Increasing
demand for infant nutrition products anticipated to boost the global
human milk oligosaccharides market
Infant
formula ingredients such as human milk oligosaccharides have been
gaining popularity in the recent past as an infant formula ingredient
to cater to the demands of the baby nutrition segment. Health
benefits associated with the consumption of human milk
oligosaccharides include maintaining gut microbiota and inhibition of
pathogen in infants. These are factors likely to drive the growth of
the global
human milk oligosaccharides market.
Human milk oligosaccharides are gaining traction due to the potential
benefits by consumption such as a prebiotic to maintain a healthy
immune system in infants. It also aids in blocking adhesion of
microbial pathogens and foreign particles to epithelial surfaces,
thus improving gut colonisation.
Human
milk oligosaccharides (HMO) is a better alternative for non-lactating
mothers as it has all the nutrients required by infants for normal
growth. Manufacturers are producing HMOs by various chemical
synthesis and fermentation processes in order to cater to the demand
for infant formula ingredients. According to the WHO, the total world
population is estimated to increase by approximately one billion in
the next 10 years and reach 9.5 billion by 2050. The constantly
growing population is likely to increase demand for infant nutrition
products. The demand for infant formula is significantly high in
China as well as in certain countries in the Asia Pacific owing to a
high infant population.
High
prices owing to costly chemical synthesis and the presence of
substitutes with the same potential and functional benefits are
hampering the growth of the global human milk oligosaccharides market
Fill
the form to gain deeper insights on this market @
http://www.futuremarketinsights.com/reports/sample/rep-gb-4252
Human
milk oligosaccharides are the third largest component of human milk,
but cannot be synthesised directly through human milk due to low
availability of a donor group. Currently, manufacturers are
developing technologies to produce human milk oligosaccharides
through chemical and enzymatic synthesis. These synthetic and
enzymatic methods require high capital and resources, but the final
product produced is in relatively low quantity. For instance,
enzymatic synthesis is required for costly substrates such as
glycosyltransferases and this is one of the major factors attributed
to the high price of human milk oligosaccharides.
Infant
formula ingredients such as galactooligosaccharides and
fructooligosaccharides are used as prebiotics in infant formula to
reduce the growth of pathogenic Escherichiacoli. Consumption of these
offers health benefits for the gastrointestinal tract of infants by
stimulating the growth of selected micro-organisms in intestinal
microflora. Manufacturers of infant formula are using these as
substitutes to human milk oligosaccharides due to the low cost and
high availability. Hence, these alternatives to human milk
oligosaccharides with the same functional benefits is restricting the
growth of the overall market to a large extent.
Fucosyllactose
segment is the largest segment with close to 50% market share in the
global human milk oligosaccharides market
Among
the various product type segments, the fucosyllactose segment is
estimated to account for a market share of almost 48% in terms of
value, followed by the sialyllactose segment with a value share of
around 28% by 2017 end. The fucosyllactose product type segment is
estimated to be valued at more than US$ 9 Mn by the end of 2017 and
is projected to increase at a CAGR of 14.4% over the period of
assessment. On the other hand, the sialyllactose segment is estimated
to be valued at more than US$ 5 Mn by the end of 2017 and is
anticipated to increase at a CAGR of 15.1% over the forecast period
and be valued at more than US$ 20 Mn by the end of 2027.
No comments:
Post a Comment